eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2015
vol. 19
 
Share:
Share:
abstract:
Original paper

Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro

Ewelina A. Hoffman
,
Katarzyna Gizelska
,
Marek Mirowski
,
Wojciech Mielicki

Contemp Oncol (Pozn) 2015; 19 (2): 108–112
Online publish date: 2015/05/13
View full text Get citation
 
PlumX metrics:
The aim of the study: To analyze human breast cancer cell line MCF-7 and human malignant melanoma cell line WM-115 in order to characterize the cellular expression of CP and to evaluate whether ATO may affect this activity, as well as the viability of the cells.

Material and methods: The inhibitory effect of arsenic trioxide on the proliferation of MCF-7 and WM-115 cells were measured with MTT test. The activity of cancer procoagulant after ATO exposure was determined by a specific three-stage chromogenic assay.

Results: ATO decreased the CP activity in a dose- and time-dependent manner in MCF-7 cells with no effect on cell proliferation at the same time. However, it affected the CP activity of WM-115 cells in a different way. Reduction in CP activity was followed by an increase after 48 h incubation. The cells viability results showed dose- and time-correlated response within high arsenic concentrations.

Conclusions: Arsenic trioxide downregulates the CP expression in human breast cancer and melanoma cells.
keywords:

arsenic trioxide, cancer procoagulant, breast cancer, melanoma

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.